All posts by : Adherium
With nearly 40 published peer-reviewed journal articles under its belt, Adherium is hoping that the latest clinical data which underlines the ability of the company’s Smartinhaler to improve outcomes for.
Gabriella Rogers reports on a new combination treatment for asthma sufferers. Click here to watch the story.
Chief Executive Officer and Co-founder, Garth Sutherland is scheduled to speak at the Australia Biotech Invest 2016 conference being to be held on 26-27 October, 2016 at the Melbourne Convention Centre, in.
Melbourne, Australia, 13 June 2016: Adherium Limited (ASX: ADR), a global leader in digital health technologies that address sub- optimal medication use in chronic disease, today announced that AstraZeneca will.
5,700 Adherium Smartinhaler™ devices plus associated software and communications technologies to be supplied through to 2018 Study in New Zealand, Australia, the United Kingdom & Italy Supply agreement with leading.
New Independent Data on Adherium Smartinhaler™ Clinical Outcomes Shows Increased Adherence and Reduction in Severe Attacks
September 30, 2015 – Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease; today announced that data from three independent.
August 26, 2015 – Digital health company Adherium Limited (ASX:ADR) ended its first day on the Australian Securities Exchange today with a closing price of 60 cents per share, a.
August 5, 2015 – Australians and New Zealanders have an opportunity to invest in a highly promising digital health technology company that substantially improves medication adherence and patient health outcomes.
July 23, 2015 – New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader AstraZeneca in what the company believes is a world-first commercial arrangement.